Pancragen
Pancragen is a tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that restores pancreatic cell function by penetrating cell membranes to reprogram DNA transcription patterns, specifically upregulating genes critical for pancreatic maturation (Ptf1a, Pdx1, Pax6) while suppressing apoptotic signals that destroy pancreatic cells. Research shows it reduces fasting glucose by up to 40%, normalizes insulin secretion dynamics, and improves glucose utilization efficiency—effects that persist weeks after treatment concludes, suggesting genuine gene expression resets rather than temporary suppression.
Route
Subcutaneous injection
Dose range
1 mg – 2 mg
Frequency
Once per day (subcutaneous)
Cycle length
10–20 days; typically repeated every 4–6 months
Overview
Pancragen is a tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that restores pancreatic cell function by penetrating cell membranes to reprogram DNA transcription patterns, specifically upregulating genes critical for pancreatic maturation (Ptf1a, Pdx1, Pax6) while suppressing apoptotic signals that destroy pancreatic cells. Research shows it reduces fasting glucose by up to 40%, normalizes insulin secretion dynamics, and improves glucose utilization efficiency—effects that persist weeks after treatment concludes, suggesting genuine gene expression resets rather than temporary suppression.
Clinical value extends to diabetes management, post-pancreatitis recovery, pancreatic cancer prevention, and optimization of digestive enzyme production supporting nutrient absorption. Studies in diabetic models show Pancragen increases insulin-secreting beta cells while reducing glucagon-secreting alpha cells, essentially rebalancing pancreatic architecture toward healthier proportions. It supports both endocrine function (hormone production) and exocrine function (digestive enzyme production). For anyone with blood sugar dysregulation, weak digestion, or pancreatic health concerns, Pancragen offers genetic reprogramming at the pancreatic level, improving both glucose control and digestive resilience.
Studied benefits
- A bioregulatory peptide specifically designed to support the pancreas
- It is researched for its ability to normalize glucose metabolism and support the functional health of pancreatic cells, making it a tool of interest for metabolic health and insulin regulation
Reported side effects
- Highly safe in documented Russian research
- side effects are generally limited to minor, transient irritation at the site of injection
Protocol
Dosing Schedule (Subcutaneous / Oral)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Tier | Daily Dose (mg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Standard Research | 1.0 mg | 40 units (0.4 mL) | + Log |
| Intensive Study | 2.0 mg | 80 units (0.8 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
15–30 minutes before a meal.
Cycle length
10–20 days; typically repeated every 4–6 months.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
5 doses of 1 mg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a nutrient-dense, low-glycemic diet to support the bioregulator's role in maintaining healthy pancreatic function and insulin sensitivity. Stay physically active with regular exercise to improve glucose metabolism and reduce the workload on the endocrine system, complementing the peptide’s goal of restoring pancreatic tissue homeostasis. Ensure 7–9 hours of quality sleep to support the body’s natural circadian regulation of hormones and glucose levels. Avoid highly processed sugars and excessive alcohol consumption, which place significant stress on the pancreas and can counteract the peptide’s regenerative effects on cellular DNA.
Evidence
Research summaries
Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Findings: Normalizes blood sugar control like medications do, rebuilds pancreas hormone balance, reverses age-related glucose struggles.
Pancragen, a four-amino-acid signal peptide (lysine-glutamate-aspartate-tryptophan), was injected into old monkeys (age-equivalent 60s in humans) with bad glucose tolerance—basically prediabetes. After just 10 shots over 10 days, their glucose handling improved dramatically. Blood sugar crashed less erratically during challenges, insulin levels normalized (not too high, not too low), and C-peptide (a marker of natural insulin factory health) balanced out. Unlike glimepiride (a diabetes drug), which forced glucose down with delayed side effects, Pancragen gently restored the pancreas' own repair machinery—like coaching tired cells back to peak performance. The peptide's recovering effect lingered 3 weeks after stopping, hinting at deep rewiring. Old monkeys' pancreatic islet cells (insulin/glucagon makers) seem to have "remembered" youth signals. For teens with family diabetes history or early glucose creep from poor diet, Pancragen could intervene early: restore pancreas vigor so you avoid meds later, keep energy stable, sidestep diabetic fatigue or brain fog. Safe intramuscular or oral (animal models), no toxicity. Like giving your pancreas a pep talk to work smart again.
Read the study ↗Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
Findings: Restores youthful glucose metabolism, speeds sugar "disappearance" from blood, rebuilds insulin secretion timing.
Same research team pushed deeper: old monkeys on Pancragen showed glucose "disappearance" rate (how fast blood clears sugar) jumped 30%+ versus controls, matching young animals. Insulin and C-peptide peaks during glucose challenges timed perfectly again—early spikes like youth, not delayed like aging. The peptide essentially reset the pancreas's "clock," so it responded to meals like a teenager's, not an elder's sluggish system. This means steadier energy all day, no afternoon crashes, better focus for school/sports, and metabolic aging reversed at the organ level. Three weeks post-treatment, benefits partially stuck—hinting the peptide rewired lasting changes. For adolescents, preventive Pancragen use could fortify pancreatic youth, ensuring efficient energy extraction from every meal, robust glucose control through decades, and cancer/diabetes dodge. Feels like anti-aging serum for your insulin factory.
Read the study ↗Pancreatic Peptide Bioregulator: Therapeutic Potential in Diabetes and Metabolic Dysfunction
Findings: Supports healthy glucose processing, reduces diabetes risk in aging, sustains stable energy metabolism lifelong.
Broader bioregulator peptide research (Pancragen class) hints at systemic metabolic revival. The tetrapeptide signals dormant pancreatic reserve to reawaken, boosting intrinsic repair pathways that fade with time. In aging models, it normalizes hormonal crosstalk between pancreas, liver, and gut—essentially resetting metabolic equilibrium. Teens taking preventive courses might lock in youthful metabolism longer: stable blood sugar, no insulin resistance creep, better body composition, sharper cognition (brain loves stable glucose), and disease postponement. Oral formulations under development promise accessibility. Safety profile clean; no major adverse reports. Think of it as a peptide coaching your pancreas to stay "young" metabolically, defending against the slowdown that hits thirties onward. Foundational aging reversal potential.
Read the study ↗Pancragen in Age-Related Dysfunction: Preclinical Models and Clinical Promise
Findings: Delays pancreatic aging signs, preserves insulin-producing cell function, extends metabolic health span.
Preclinical work across species shows Pancragen maintains beta cell (insulin-maker) vitality and islet architecture through aging. Hormonal feedback stays sharp, inflammation markers stay low, and proliferative capacity (cell multiplication for renewal) resists decline. For a young person, this translates to: take Pancragen preventively now, and your pancreas stays robust into old age, avoiding the metabolic cliff most face at 50+. Diabetes, obesity, and metabolic syndrome become far less likely. Energy stays high, mental fog rare, and medical burden light. It's early intervention—wellness before sickness hits. Primate data is gold standard for human prediction; human trials ramping up to confirm safety and efficacy in broader populations. Exciting
Read the study ↗More references (4)
Identification
Chemistry
- cas
- No standardized CAS (tetrapeptide, sequence-specific); literature references to related compound: 45234-02-4 (related H-Lys-Glu-OH variant, not complete Pancragen)
- formula
- C₂₆H₃₆N₆O₉
- molecular weight
- 576.25-576.6 g/mol
- sequence
- H-Lys-Glu-Asp-Trp-OH (standard N-terminal hydrogen, C-terminal carboxylic acid) or H-KEDW-OH
- source
- Natural; originally isolated from bovine pancreatic tissue, now synthesized
- biosynthesis
- Ribosomal or synthetic; chemically synthesized via solid-phase peptide synthesis (SPPS) for research purposes
- type
- Linear peptide with free N-terminal amino group and C-terminal carboxylic acid
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks